凤凰网首页 手机凤凰网

凤凰卫视
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
免费注册
华兰生物(002007)公告正文

华兰生物:2013年第一季度报告全文

公告日期 2013-04-25
股票简称:华兰生物 股票代码:002007
                华兰生物工程股份有限公司 2013 年第一季度报告全文华兰生物工程股份有限公司
    2013 年第一季度报告
      2013 年 04 月
                                                   华兰生物工程股份有限公司 2013 年第一季度报告全文
                                   第一节 重要提示
    公司董事会、监事会及董事、监事、高级管理人员应当保证季度报告内容的真实、准确、完整,不存在虚假记载、误导性陈述或者重大遗漏,并承担个别和连带的法律责任。
    公司负责人安康、主管会计工作负责人王启平及会计机构负责人(会计主管人员)桑莉声明:保证季度报告中财务报表的真实、准确、完整。
    除下列董事外,其他董事亲自出席了审议本次季报的董事会会议
    未亲自出席董事姓名     未亲自出席董事职务     未亲自出席会议原因           被委托人姓名
        李德新                独立董事               工作原因                    苏志国
         安颖                   董事                 工作原因                     安康
                                                                  华兰生物工程股份有限公司 2013 年第一季度报告全文
                             第二节 主要财务数据及股东变化一、主要财务数据本报告期对以前期间财务数据是否进行了追溯调整或重述□ 是 √ 否
                                                                                               本报告期比上年同期增减
                                         2013 年 1-3 月               2012 年 1-3 月
                                                                                                       (%)
    营业收入(元)                                292,469,257.21                274,065,826.40                       6.71%
    归属于上市公司股东的净利润(元)              130,990,154.36                130,382,956.86                       0.47%归属于上市公司股东的扣除非经常性损
                                              126,130,587.15                127,512,630.07                       -1.08%益的净利润(元)
    经营活动产生的现金流量净额(元)               111,949,445.95               156,077,109.98                      -28.27%
    基本每股收益(元/股)                                 0.2273                        0.2263                       0.44%
    稀释每股收益(元/股)                                 0.2273                        0.2263                       0.44%
    加权平均净资产收益率(%)                                 4.92%                        5.36%                     -0.44%
                                                                                               本报告期末比上年度期末
                                       2013 年 3 月 31 日           2012 年 12 月 31 日
                                                                                                      增减(%)
    总资产(元)                                 3,260,932,278.41             2,962,677,475.26                      10.07%
    归属于上市公司股东的净资产(元)             2,728,699,878.06             2,597,709,723.70                       5.04%非经常性损益项目和金额√ 适用 □ 不适用
                                                                                                                单位:元
                         项目                               年初至报告期期末金额                     说明
    非流动资产处置损益(包括已计提资产减值准备的冲销部分)                      -4,197.20计入当期损益的政府补助(与企业业务密切相关,按照国家统
                                                                           279,000.00一标准定额或定量享受的政府补助除外)
    除上述各项之外的其他营业外收入和支出                                      -138,607.52
    其他符合非经常性损益定义的损益项目                                       6,213,655.71
    所得税影响额                                                               969,503.86
    少数股东权益影响额(税后)                                                 520,779.92
    合计                                                                     4,859,567.21                  --二、报告期末股东总数及前十名股东持股情况表
                                                                                                                单位:股
                                                               华兰生物工程股份有限公司 2013 年第一季度报告全文
    报告期末股东总数                                                                                            51,089
                                             前 10 名股东持股情况
                                                             持股比                持有有限售条    质押或冻结情况
                   股东名称                    股东性质               持股数量
                                                            例(%)                件的股份数量 股份状态     数量
    新乡市华兰生物技术有限公司                 境内非国有法人    17.83% 102,723,822               0
    新乡市金康生物科技开发有限公司             境内非国有法人    15.27%   87,961,115              0
    香港科康有限公司                           境内非国有法人    13.34% 76,889,088                0
    新乡市世辰生物技术有限公司                 境内非国有法人     4.27%   24,604,400              0中国工商银行-汇添富均衡增长股票型证券投
                                           境内非国有法人     1.54%    8,877,877              0资基金中国人民财产保险股份有限公司-传统-普通
                                           境内非国有法人     1.35%    7,799,382              0保险产品中国人民人寿保险股份有限公司-分红-个险
                                           境内非国有法人     1.08%    6,239,035              0分红中国工商银行-汇添富医药保健股票型证券投
                                           境内非国有法人     1.06%    6,100,000              0资基金
    中国银行-大成蓝筹稳健证券投资基金         境内非国有法人     0.87%    4,998,954              0中国农业银行-汇添富社会责任股票型证券投
                                           境内非国有法人     0.71%    4,062,636              0资基金
                                      前 10 名无限售条件股东持股情况
                                                                                              股份种类
                        股东名称                          持有无限售条件股份数量
                                                                                        股份种类         数量
    新乡市华兰生物技术有限公司                                              102,723,822 人民币普通股       102,723,822
    新乡市金康生物科技开发有限公司                                           87,961,115 人民币普通股         87,961,115
    香港科康有限公司                                                         76,889,088 人民币普通股         76,889,088
    新乡市世辰生物技术有限公司                                               24,604,400 人民币普通股         24,604,400
    中国工商银行-汇添富均衡增长股票型证券投资基金                            8,877,877 人民币普通股          8,877,877
    中国人民财产保险股份有限公司-传统-普通保险产品                          7,799,382 人民币普通股          7,799,382
    中国人民人寿保险股份有限公司-分红-个险分红                              6,239,035 人民币普通股          6,239,035
    中国工商银行-汇添富医药保健股票型证券投资基金                            6,100,000 人民币普通股          6,100,000
    中国银行-大成蓝筹稳健证券投资基金                                        4,998,954 人民币普通股          4,998,954
    中国农业银行-汇添富社会责任股票型证券投资基金                            4,062,636 人民币普通股          4,062,636
                                                      上述第一、二、三、四股东存在关联关系,属于一致行动人。
                                                      中国工商银行-汇添富均衡增长股票型证券投资基金和中国上述股东关联关系或一致行动的说明
                                                      工商银行-汇添富医药保健股票型证券投资基金、中国农业银
                                                      行-汇添富社会责任股票型证券投资基金同为汇添富基金管
       华兰生物工程股份有限公司 2013 年第一季度报告全文理有限公司旗下基金。未知其他股东之间是否存在关联关系,是否属于一致行动人。
                                                                 华兰生物工程股份有限公司 2013 年第一季度报告全文
                                            第三节 重要事项一、报告期主要会计报表项目、财务指标发生重大变动的情况及原因1、应收票据期末余额较期初余额减少87.73%,主要是本公司票据背书或到期结算所致。2、应收账款期末余额较期初余额增长88.94%,主要是应收款项未到结算期所致。3、其他应收款期末余额较期初余额减少90.01%,主要是本公司支付的土地保证金结算所致。4、生产性生物资产期末余额较期初余额减少46.93%,主要是本公司之孙公司新乡市太行禽业有限公司处理成鸡所致。5、无形资产期末余额较期初余额增长45.82%,主要是本公司土地使用权增加所致。6、短期借款期末余额较期初余额增长1.4亿元,主要是本公司之子公司华兰生物工程重庆有限公司借款增加所致。7、应付票据期末余额较期初余额增长1,036.8万元,主要是银行票据支付货款所致。8、应付职工薪酬期末余额较期初余额增长55.63%,主要是本公司计提工会经费所致。9、应交税费期末余额较期初余额增长129.86%,主要是税款未到缴纳期所致。10、营业成本报告期较上年同期增长85.16%,主要是本公司之子公司华兰生物工程重庆有限公司上年同期未投产销售所致。11、营业税金及附加报告期较上年同期减少59.20%,主要一是本公司及部分子、孙公司自2013年1月1日起增值税征收方式变更为简易征收,即按6%计算缴纳增值税;二是本公司之子公司华兰生物疫苗有限公司上年同期确认甲型H1N1流感病毒裂解疫苗收入1.06亿元,而本报告期无此收入所致。12、销售费用报告期较上年同期减少69.20%,主要是公司广告费、差旅费及运输费等较上年同期减少所致。13、财务费用报告期较上年同期减少116.36%,主要是存款利息收入增加所致。14、投资收益报告期较上年同期减少36.22%,主要是理财产品收益减少所致。15、营业外收入报告期较上年同期减少72.51%,主要是收到政府补助减少所致。16、营业外支出报告期较上年同期减少93.46%,主要是非流动资产处置减少所致。17、所得税费用报告期较上年同期减少36.16%,主要是本公司之子公司华兰生物疫苗有限公司上年同期确认甲型H1N1流感病毒裂解疫苗收入1.06亿元,而本报告期无此收入所致。18、收到的其他与经营活动有关的现金报告期较上年同期增加133.87%,主要是存款利息收入增加所致。二、公司或持股 5%以上股东在报告期内或持续到报告期内的承诺事项
      承诺事项         承诺方                         承诺内容                      承诺时间 承诺期限 履行情况
    股改承诺               不适用                          不适用                                  不适用     不适用收购报告书或权益变
                       不适用                          不适用                                  不适用     不适用动报告书中所作承诺
    资产重组时所作承诺     不适用                          不适用                                  不适用     不适用
                                  为避免同业竞争引起的损害本公司及其他股东利益,
                                  本公司实际控制人安康先生承诺:"作为本公司实际控
    首次公开发行或再融                制人期间,不在与本公司构成同业竞争的其他公司任 2004 年 06              正在严格
                     实际控制人                                                               长期有效
    资时所作承诺                      职,在其经营业务中将不会利用其在本公司及本公司 月 25 日                履行中
                                  股东中的地位从事任何有损本公司及其他股东利益的
                                  行为。"
    其他对公司中小股东   董事会       公司未来三年(2012-2014 年)的具体股东回报规划:2012 年 08 2012-2014 正在严格
                                                              华兰生物工程股份有限公司 2013 年第一季度报告全文
    所作承诺                        1、公司可以采取现金、股票、现金与股票相结合或者 月 29 日   年度      履行中
                                法律、法规允许的其他方式分配利润。2、根据《公司
                                法》等有关法律法规及《公司章程》的规定,在公司
                                盈利且现金能够满足公司持续经营和长期发展、符合
                                现金分红条件的前提下,2012-2014 年每年以现金方式
                                分配的利润应不低于当年实现的可分配利润的 10%,
                                且连续三年内以现金方式累计分配的利润不少于该三
                                年实现的年均可分配利润的 30%。 3、未来三年
                                (2012-2014 年)公司原则上每年度进行一次现金分
                                红,公司董事会可以根据公司盈利情况及资金需求状
                                况提议公司进行中期现金分红。 4、未来三年
                                (2012-2014)公司可以根据累计可供分配利润、公积
                                金及现金流状况,在保证最低现金分红比例和公司股
                                本规模合理的前提下,为保持股本扩张与业绩增长相
                                适应,公司可以采取股票股利方式进行利润分配,具
                                体分红比例由公司董事会审议通过后,并提交股东大
                                会审议决定。
    承诺是否及时履行                                                是未完成履行的具体原
                                                              不适用因及下一步计划是否就导致的同业竞
    争和关联交易问题作                                              是出承诺
    承诺的解决期限                                                不适用
    解决方式                                                      不适用
    承诺的履行情况                                             严格履行承诺三、对 2013 年 1-6 月经营业绩的预计2013 年 1-6 月预计的经营业绩情况:归属于上市公司股东的净利润为正值且不属于扭亏为盈的情形归属于上市公司股东的净利润为正值且不属于扭亏为盈的情形2013 年 1-6 月归属于上市公司股东的净利润变动幅度
                                                                       0%    至                           30%(%)2013 年 1-6 月归属于上市公司股东的净利润变动区间
                                                                17,462.38    至                      22,701.09(万元)
    2012 年 1-6 月归属于上市公司股东的净利润(万元)                                                     17,462.38
                                           公司预计 2013 年 1-6 月份归属于上市公司股东的净利润同比增长 0%-30%,
                                           主要原因是公司全资子公司华兰生物工程重庆有限公司血液制品自 2012业绩变动的原因说明
                                           年 9 月开始实现销售,2013 年 1-6 月份血液制品销售收入较上年同期增加
                                           所致。
                                                         华兰生物工程股份有限公司 2013 年第一季度报告全文
                                     第四节 财务报表一、财务报表1、合并资产负债表编制单位:华兰生物工程股份有限公司
                                                                                                    单位:元
                 项目                    期末余额                                期初余额流动资产:
    货币资金                                         905,653,017.93                          747,946,594.28
    结算备付金
    拆出资金
    交易性金融资产
    应收票据                                           7,453,537.26                           60,723,956.50
    应收账款                                         238,329,081.66                          126,142,394.44
    预付款项                                         110,364,928.62                           86,437,644.61
    应收保费
    应收分保账款
    应收分保合同准备金
    应收利息
    应收股利
    其他应收款                                         3,626,529.73                           36,318,582.57
    买入返售金融资产
    存货                                             308,029,933.12                          314,840,624.47
    一年内到期的非流动资产
    其他流动资产                                     564,700,000.00                          419,700,000.00
    流动资产合计                                        2,138,157,028.32                        1,792,109,796.87非流动资产:
    发放委托贷款及垫款
    可供出售金融资产
    持有至到期投资
    长期应收款
    长期股权投资
                              华兰生物工程股份有限公司 2013 年第一季度报告全文
    投资性房地产
    固定资产              778,131,064.10                        792,353,871.22
    在建工程               70,688,537.72                         54,598,402.95
    工程物资
    固定资产清理
    生产性生物资产            702,209.98                          1,323,158.53
    油气资产
    无形资产              130,352,058.41                         89,390,865.81
    开发支出
    商誉
    长期待摊费用
    递延所得税资产         22,901,379.88                         22,901,379.88
    其他非流动资产        120,000,000.00                        210,000,000.00
    非流动资产合计           1,122,775,250.09                     1,170,567,678.39
    资产总计                 3,260,932,278.41                     2,962,677,475.26流动负债:
    短期借款              140,000,000.00
    向中央银行借款
    吸收存款及同业存放
    拆入资金
    交易性金融负债
    应付票据               10,368,000.00
    应付账款               43,728,312.50                         46,643,620.47
    预收款项               20,782,466.43                         19,008,932.61
    卖出回购金融资产款
    应付手续费及佣金
    应付职工薪酬              367,775.29                           236,307.19
    应交税费                3,628,464.31                        -12,151,945.83
    应付利息
    应付股利
    其他应付款             79,663,326.47                         78,101,742.24
    应付分保账款
    保险合同准备金
    代理买卖证券款
                                                              华兰生物工程股份有限公司 2013 年第一季度报告全文
    代理承销证券款
    一年内到期的非流动负债
    其他流动负债
    流动负债合计                                              298,538,345.00                          131,838,656.68非流动负债:
    长期借款
    应付债券
    长期应付款
    专项应付款
    预计负债
    递延所得税负债
    其他非流动负债非流动负债合计
    负债合计                                                  298,538,345.00                          131,838,656.68所有者权益(或股东权益):
    实收资本(或股本)                                   576,204,800.00                          576,204,800.00
    资本公积                                             291,337,232.03                          291,337,232.03
    减:库存股
    专项储备
    盈余公积                                             212,864,965.34                          212,864,965.34
    一般风险准备
    未分配利润                                          1,648,292,880.69                        1,517,302,726.33
    外币报表折算差额
    归属于母公司所有者权益合计                               2,728,699,878.06                        2,597,709,723.70
    少数股东权益                                         233,694,055.35                          233,129,094.88
    所有者权益(或股东权益)合计                             2,962,393,933.41                        2,830,838,818.58负债和所有者权益(或股东权益)总
                                                         3,260,932,278.41                        2,962,677,475.26计
    法定代表人:安康                     主管会计工作负责人:王启平                         会计机构负责人:桑莉2、母公司资产负债表编制单位:华兰生物工程股份有限公司
                                                                                                         单位:元
                  项目                        期末余额                                期初余额
                                  华兰生物工程股份有限公司 2013 年第一季度报告全文流动资产:
    货币资金                  744,789,053.47                        488,811,604.84
    交易性金融资产
    应收票据                    7,453,537.26                         59,723,956.50
    应收账款                   81,467,619.12                         56,656,347.12
    预付款项                   92,747,932.20                         72,042,467.35
    应收利息
    应收股利
    其他应收款                145,571,503.93                         91,920,281.30
    存货                      151,529,046.66                        162,520,215.41
    一年内到期的非流动资产
    其他流动资产              190,000,000.00                        350,000,000.00
    流动资产合计                 1,413,558,692.64                     1,281,674,872.52非流动资产:
    可供出售金融资产
    持有至到期投资
    长期应收款                  5,379,060.00                          5,379,060.00
    长期股权投资              577,866,697.11                        577,866,697.11
    投资性房地产
    固定资产                  202,480,880.98                        205,822,776.19
    在建工程                   49,533,577.09                         35,769,064.09
    工程物资
    固定资产清理
    生产性生物资产
    油气资产
    无形资产                   66,914,737.76                         29,969,965.05
    开发支出
    商誉
    长期待摊费用
    递延所得税资产              3,797,456.54                          3,797,456.54
    其他非流动资产                                                   90,000,000.00
    非流动资产合计                905,972,409.48                        948,605,018.98
    资产总计                     2,319,531,102.12                     2,230,279,891.50流动负债:
                                        华兰生物工程股份有限公司 2013 年第一季度报告全文
    短期借款
    交易性金融负债
    应付票据
    应付账款                         31,870,804.27                         34,386,345.74
    预收款项                          1,232,360.00                           409,860.00
    应付职工薪酬                        141,748.98
    应交税费                          9,440,519.39                          6,553,319.77
    应付利息
    应付股利
    其他应付款                          380,413.39                           249,349.91
    一年内到期的非流动负债
    其他流动负债
    流动负债合计                         43,065,846.03                         41,598,875.42非流动负债:
    长期借款
    应付债券
    长期应付款
    专项应付款
    预计负债
    递延所得税负债
    其他非流动负债非流动负债合计
    负债合计                             43,065,846.03                         41,598,875.42所有者权益(或股东权益):
    实收资本(或股本)              576,204,800.00                        576,204,800.00
    资本公积                        300,085,029.54                        300,085,029.54
    减:库存股
    专项储备
    盈余公积                        212,864,965.34                        212,864,965.34
    一般风险准备
    未分配利润                     1,187,310,461.21                     1,099,526,221.20
    外币报表折算差额
    所有者权益(或股东权益)合计       2,276,465,256.09                     2,188,681,016.08
    负债和所有者权益(或股东权益)总   2,319,531,102.12                     2,230,279,891.50
                                                                华兰生物工程股份有限公司 2013 年第一季度报告全文计
    法定代表人:安康                         主管会计工作负责人:王启平                       会计机构负责人:桑莉3、合并利润表编制单位:华兰生物工程股份有限公司
                                                                                                         单位:元
                   项目                           本期金额                              上期金额
    一、营业总收入                                               292,469,257.21                        274,065,826.40
       其中:营业收入                                        292,469,257.21                        274,065,826.40
             利息收入
             已赚保费
             手续费及佣金收入
    二、营业总成本                                               149,029,483.86                        101,893,074.96
       其中:营业成本                                        124,574,087.23                         67,277,945.88
             利息支出
             手续费及佣金支出
             退保金
             赔付支出净额
             提取保险合同准备金净额
             保单红利支出
             分保费用
             营业税金及附加                                    1,679,910.73                          4,117,360.15
             销售费用                                          2,717,503.73                          8,823,453.54
             管理费用                                         30,886,927.64                         26,679,274.66
             财务费用                                        -10,828,945.47                         -5,004,959.27
             资产减值损失
       加   :公允价值变动收益(损失以“-”号填列)
             投资收益(损失以“-”号
                                                               4,293,655.71                          6,732,369.25填列)
             其中:对联营企业和合营企业的投资收益
             汇兑收益(损失以“-”号填列)
    三、营业利润(亏损以“-”号填列)                           147,733,429.06                        178,905,120.69
                                                                  华兰生物工程股份有限公司 2013 年第一季度报告全文
       加   :营业外收入                                          371,759.43                           1,352,540.00
       减   :营业外支出                                          235,564.15                           3,600,968.70
             其中:非流动资产处置损
                                                                     4,197.20                          3,548,712.04失四、利润总额(亏损总额以“-”号填
                                                               147,869,624.34                        176,656,691.99列)
       减:所得税费用                                           16,314,509.51                         25,555,395.03
    五、净利润(净亏损以“-”号填列)                             131,555,114.83                        151,101,296.96
       其中:被合并方在合并前实现的净利润
       归属于母公司所有者的净利润                              130,990,154.36                        130,382,956.86
       少数股东损益                                               564,960.47                          20,718,340.10
    六、每股收益:                        --                                        --
       (一)基本每股收益                                             0.2273                                0.2263
       (二)稀释每股收益                                             0.2273                                0.2263七、其他综合收益
    八、综合收益总额                                               131,555,114.83                        151,101,296.96
       归属于母公司所有者的综合收益
                                                               130,990,154.36                        130,382,956.86总额
       归属于少数股东的综合收益总额                               564,960.47                          20,718,340.10
    法定代表人:安康                           主管会计工作负责人:王启平                       会计机构负责人:桑莉4、母公司利润表编制单位:华兰生物工程股份有限公司
                                                                                                           单位:元
                  项目                              本期金额                              上期金额
    一、营业收入                                                   164,417,852.41                        164,020,767.92
       减:营业成本                                             62,190,987.27                         69,684,509.19
            营业税金及附加                                       1,317,197.81                          2,206,467.01
            销售费用                                               135,711.47                             54,738.09
            管理费用                                             9,190,286.42                          8,589,067.56
            财务费用                                           -10,817,263.15                         -4,433,916.62
            资产减值损失
       加:公允价值变动收益(损失以“-”号填列)
                                                                    华兰生物工程股份有限公司 2013 年第一季度报告全文
           投资收益(损失以“-”号填
                                                                    869,041.10                           2,688,606.02列)
           其中:对联营企业和合营企业的投资收益
    二、营业利润(亏损以“-”号填列)                               103,269,973.69                         90,608,508.71
       加:营业外收入                                                 10,000.00                           542,500.00
       减:营业外支出                                                  4,397.20                          3,585,430.04
           其中:非流动资产处置损失                                    4,197.20                          3,540,565.04三、利润总额(亏损总额以“-”号填
                                                                 103,275,576.49                         87,565,578.67列)
       减:所得税费用                                             15,491,336.48                         13,134,836.79
    四、净利润(净亏损以“-”号填列)                                87,784,240.01                         74,430,741.88
    五、每股收益:                          --                                        --
       (一)基本每股收益                                               0.1523                                0.1292
       (二)稀释每股收益                                               0.1523                                0.1292六、其他综合收益
    七、综合收益总额                                                  87,784,240.01                         74,430,741.88
    法定代表人:安康                             主管会计工作负责人:王启平                       会计机构负责人:桑莉5、合并现金流量表编制单位:华兰生物工程股份有限公司
                                                                                                             单位:元
                 项目                                 本期金额                              上期金额一、经营活动产生的现金流量:
       销售商品、提供劳务收到的现金                              263,780,295.15                        305,878,513.79
       客户存款和同业存放款项净增加额
       向中央银行借款净增加额
       向其他金融机构拆入资金净增加额
       收到原保险合同保费取得的现金
       收到再保险业务现金净额
       保户储金及投资款净增加额
       处置交易性金融资产净增加额
       收取利息、手续费及佣金的现金
                                       华兰生物工程股份有限公司 2013 年第一季度报告全文
    拆入资金净增加额
    回购业务资金净增加额
    收到的税费返还
    收到其他与经营活动有关的现金    36,715,449.81                        15,699,283.22
    经营活动现金流入小计                300,495,744.96                       321,577,797.01
    购买商品、接受劳务支付的现金    96,183,263.88                        81,005,812.58
    客户贷款及垫款净增加额
    存放中央银行和同业款项净增加额
    支付原保险合同赔付款项的现金
    支付利息、手续费及佣金的现金
    支付保单红利的现金
    支付给职工以及为职工支付的现
                                     30,858,022.67                        25,516,315.15金
    支付的各项税费                  35,283,507.90                        38,256,104.04
    支付其他与经营活动有关的现金    26,221,504.56                        20,722,455.26
    经营活动现金流出小计                188,546,299.01                       165,500,687.03
    经营活动产生的现金流量净额          111,949,445.95                       156,077,109.98二、投资活动产生的现金流量:
    收回投资收到的现金             342,000,000.00                       821,428,888.90
    取得投资收益所收到的现金         4,293,655.71                         6,732,369.25
    处置固定资产、无形资产和其他长期资产收回的现金净额
    处置子公司及其他营业单位收到的现金净额
    收到其他与投资活动有关的现金
    投资活动现金流入小计                346,293,655.71                       828,161,258.15
    购建固定资产、无形资产和其他
                                     43,111,540.73                        18,280,138.12长期资产支付的现金
    投资支付的现金                 397,000,000.00                       886,000,000.00
    质押贷款净增加额
    取得子公司及其他营业单位支付的现金净额
    支付其他与投资活动有关的现金
    投资活动现金流出小计                440,111,540.73                       904,280,138.12
    投资活动产生的现金流量净额          -93,817,885.02                       -76,118,879.97
                                                             华兰生物工程股份有限公司 2013 年第一季度报告全文三、筹资活动产生的现金流量:
       吸收投资收到的现金
       其中:子公司吸收少数股东投资收到的现金
       取得借款收到的现金                                 140,000,000.00
       发行债券收到的现金
       收到其他与筹资活动有关的现金
    筹资活动现金流入小计                                      140,000,000.00
       偿还债务支付的现金
       分配股利、利润或偿付利息支付
                                                            1,229,898.62的现金
       其中:子公司支付给少数股东的股利、利润
       支付其他与筹资活动有关的现金
    筹资活动现金流出小计                                        1,229,898.62
    筹资活动产生的现金流量净额                                138,770,101.38四、汇率变动对现金及现金等价物的
                                                              -67,202.98                           -204,086.63影响
    五、现金及现金等价物净增加额                              156,834,459.33                         79,754,143.38
       加:期初现金及现金等价物余额                       744,501,536.95                        881,398,519.85
    六、期末现金及现金等价物余额                              901,335,996.28                        961,152,663.23
    法定代表人:安康                      主管会计工作负责人:王启平                       会计机构负责人:桑莉6、母公司现金流量表编制单位:华兰生物工程股份有限公司
                                                                                                      单位:元
                 项目                          本期金额                              上期金额一、经营活动产生的现金流量:
       销售商品、提供劳务收到的现金                       200,274,950.54                        207,329,355.92
       收到的税费返还
       收到其他与经营活动有关的现金                        13,558,060.40                          5,204,351.48
    经营活动现金流入小计                                      213,833,010.94                        212,533,707.40
       购买商品、接受劳务支付的现金                        54,744,878.84                         56,769,872.31
       支付给职工以及为职工支付的现
                                                            9,450,046.47                          7,390,627.31金
                                         华兰生物工程股份有限公司 2013 年第一季度报告全文
       支付的各项税费                  23,964,437.98                        11,696,754.38
       支付其他与经营活动有关的现金    10,854,865.60                         5,206,597.26
    经营活动现金流出小计                   99,014,228.89                        81,063,851.26
    经营活动产生的现金流量净额            114,818,782.05                       131,469,856.14二、投资活动产生的现金流量:
       收回投资收到的现金             250,000,000.00                       502,840,000.00
       取得投资收益所收到的现金          869,041.10                          2,688,606.02
       处置固定资产、无形资产和其他长期资产收回的现金净额
       处置子公司及其他营业单位收到的现金净额
       收到其他与投资活动有关的现金
    投资活动现金流入小计                  250,869,041.10                       505,528,606.02
       购建固定资产、无形资产和其他
                                       28,678,147.70                         8,778,533.03长期资产支付的现金
       投资支付的现金                                                      580,000,000.00
       取得子公司及其他营业单位支付的现金净额
       支付其他与投资活动有关的现金    80,000,000.00
    投资活动现金流出小计                  108,678,147.70                       588,778,533.03
    投资活动产生的现金流量净额            142,190,893.40                       -83,249,927.01三、筹资活动产生的现金流量:
       吸收投资收到的现金
       取得借款收到的现金
       发行债券收到的现金
       收到其他与筹资活动有关的现金筹资活动现金流入小计
       偿还债务支付的现金
       分配股利、利润或偿付利息支付的现金
       支付其他与筹资活动有关的现金筹资活动现金流出小计筹资活动产生的现金流量净额四、汇率变动对现金及现金等价物的
                                          -67,191.14                          -204,086.63影响
    五、现金及现金等价物净增加额          256,942,484.31                        48,015,842.50
                                                          华兰生物工程股份有限公司 2013 年第一季度报告全文
    加:期初现金及现金等价物余额                     485,366,547.51                        704,108,696.11
    六、期末现金及现金等价物余额                          742,309,031.82                        752,124,538.61
    法定代表人:安康                    主管会计工作负责人:王启平                      会计机构负责人:桑莉二、审计报告第一季度报告是否经过审计□ 是 √ 否
                                                                                 华兰生物工程股份有限公司
                                                                                              董事长:安康
                                                                                          2013 年 4 月 25 日
数据加载中...
prevnext
手机查看股票